These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

311 related items for PubMed ID: 24158513

  • 1. Globotriaosylceramide induces lysosomal degradation of endothelial KCa3.1 in fabry disease.
    Choi S, Kim JA, Na HY, Cho SE, Park S, Jung SC, Suh SH.
    Arterioscler Thromb Vasc Biol; 2014 Jan; 34(1):81-9. PubMed ID: 24158513
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Pathogenesis and Molecular Mechanisms of Anderson-Fabry Disease and Possible New Molecular Addressed Therapeutic Strategies.
    Tuttolomondo A, Simonetta I, Riolo R, Todaro F, Di Chiara T, Miceli S, Pinto A.
    Int J Mol Sci; 2021 Sep 18; 22(18):. PubMed ID: 34576250
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. An in vitro model of Fabry disease.
    Shu L, Murphy HS, Cooling L, Shayman JA.
    J Am Soc Nephrol; 2005 Sep 18; 16(9):2636-45. PubMed ID: 16033856
    [Abstract] [Full Text] [Related]

  • 6. Molecular basis for globotriaosylceramide regulation and enzyme uptake in immortalized aortic endothelial cells from Fabry mice.
    Meng XL, Day TS, McNeill N, Ashcraft P, Frischmuth T, Cheng SH, Liu ZP, Shen JS, Schiffmann R.
    J Inherit Metab Dis; 2016 May 18; 39(3):447-455. PubMed ID: 26960552
    [Abstract] [Full Text] [Related]

  • 7. Distributions of Globotriaosylceramide Isoforms, and Globotriaosylsphingosine and Its Analogues in an α-Galactosidase A Knockout Mouse, a Model of Fabry Disease.
    Sueoka H, Aoki M, Tsukimura T, Togawa T, Sakuraba H.
    PLoS One; 2015 May 18; 10(12):e0144958. PubMed ID: 26661087
    [Abstract] [Full Text] [Related]

  • 8. Vascular dysfunction in the alpha-galactosidase A-knockout mouse is an endothelial cell-, plasma membrane-based defect.
    Park JL, Whitesall SE, D'Alecy LG, Shu L, Shayman JA.
    Clin Exp Pharmacol Physiol; 2008 Oct 18; 35(10):1156-63. PubMed ID: 18565198
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Lyso-globotriaosylceramide downregulates KCa3.1 channel expression to inhibit collagen synthesis in fibroblasts.
    Choi JY, Shin MY, Suh SH, Park S.
    Biochem Biophys Res Commun; 2015 Dec 25; 468(4):883-8. PubMed ID: 26592662
    [Abstract] [Full Text] [Related]

  • 12. The endothelium at the brink of calamity in storage disease: more than just overloaded with junk?
    de Wit C.
    Cardiovasc Res; 2011 Feb 01; 89(2):258-9. PubMed ID: 21148146
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Enhanced thrombospondin-1 causes dysfunction of vascular endothelial cells derived from Fabry disease-induced pluripotent stem cells.
    Do HS, Park SW, Im I, Seo D, Yoo HW, Go H, Kim YH, Koh GY, Lee BH, Han YM.
    EBioMedicine; 2020 Feb 01; 52():102633. PubMed ID: 31981984
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding disorder.
    Yam GH, Zuber C, Roth J.
    FASEB J; 2005 Jan 01; 19(1):12-8. PubMed ID: 15629890
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.